Ketorolac is a potent non-steroidal anti-inflammatory drug which is indicated for the management of oderate to severe acute pain that requires analgesia at the opioid level.
K LAC Tablet: Each tablet contains Ketorolac Tromethamine USP equivalent to 10 mg Ketorolac. K LAC IM/IV Injection: Each ml Ampoule contains Ketorolac Tromethamine USP 30mg Ketorolac . K LAC 60 IM/IV Injection: Each 2 ml Ampoule contains Ketorolac Tromethamine USP 60mg.
K LAC (Ketorolac Tromethamine) is a non-steroida anti-inflammatory drug that exhibits analgesic activity. Ketorolac Tromethamine inhibits synthesis of prostaglandins and may be considered a peripherally acting analgesic. Ketorolac Tromethamine possesses no sedative or anxiolytic properties.
K LAC is indicated for short term management of moderate to severe acute postoperative pain and other acute pains.
Dosage and administration:
By mouth, 10 mg every 4-6 hours (the elderly every 6-8 hours): max. 40mg daily; Maximum duration of treatment 7 days. Byintravenous/intramuscular injection over not less than 15 seconds,initially 10 mg, then 10-30 mg every 4-6 hours when required (every 2 hours in intial postoperative period); max. 90 mg. daily (the elderly and patients wt. less than 50 Kg max. 60 mg daily); max. duration of treatment 2 days by either route. When converting from parenteral to oral administration, total combined dose on the day converting should not exceed 90 mg (60 mg in the elderly and patients wt. less than 50 kg) of which the oral component should not exceed 40 mg; patients should be converted to oral route as soon as possible.
Klac is contraindicated in patients who are hypersensitive to any component of this product. It is also contraindicated in patients with history of asthma, complete or partial syndrome of nasal polyps, angioedema or bronchospasm, history of peptic ulceration or gastroin-testinal bleeding, moderate or severe renal impairment, hypovolaemia or dehydration, pregnancy (including labour and delivery) and breast-feeding.
Ketorolac should not be given to patients already receiving anticoagulants, or to those who will require prophylactic anticoagulant therapy, including low dose heparin. The irsk of ketorolac associated bleeding is increased by other NSAIDs or aspirin and by pentoxifylling and thus concomitant use should be avoided.
Anaphylaxis, dry mouth, excessive thirst, hyponatremia, hyperkalaemia, flushing or pallor, bradycardia, hypertension, palpitations, chestpain, purpura , postoperative wound haemorrhage.
Ketorolac should be used with caution in heart failure, hepatic impairment and conditions leading to reduction in blood volume or in renal blood flow. The dose of Ketorolac should be low incase of the elderly and in patients wt. less than 50 kg. It is recommended that patients with mild renal impairment should receive are due dose of Ketorolac and undergo close monitoring of renal function.
Use in pregnancy and lactation:
Ketorolac is contraindicated in the later stages of pregnancy and should only be used earlier in the pregnancy if there are compelling reasons. Because of the possible adverse effects of prostaglandin-inhibiting drugs on neonates, use in nursing mother is contraindicated.
Safety and effectiveness have not been established in paediatric patients below the ages of 17 years. The elderly : Dose of ketorolac should not exceed 60 mg daily in the elderly.
Store in a cool and dry place, protect from light. Keep out of the reach of children.
K LAC tablet : Box containing 3 x 10’s tablets in blister pack
K LAC IM/IV Injection: Box containing 1ml x 1 ampoule and 1ml x 5 ampoules in blister pack
K LAC 60 mg IM/IV Injection: Box containing 2 ml x 2 ampoules in blister pack.